Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Clinical trial NCT03600155 · COMPLETED

Trial details

NCT number: NCT03600155
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Allogeneic Hematopoietic Stem Cell Transplantation Recipient Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia

Start date: 2018-10-11
Primary completion: 2024-12-02
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.